Literature DB >> 22997374

Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis.

Cher Heng Tan1, Wei Wei, Valen Johnson, Vikas Kundra.   

Abstract

OBJECTIVE: The objective of our study was to estimate and compare the performance of diffusion-weighted imaging (DWI) with other MRI techniques including T2-weighted MRI for the detection of prostate cancer.
MATERIALS AND METHODS: Searches of the PubMed and Scopus electronic databases for the terms "prostate," "cancer," "diffusion-weighted imaging," and "magnetic resonance imaging" using an end date of December 2010 were completed. All included studies had histopathologic correlation; 2×2 contingency data were constructed for each study. A Bayesian receiver operating characteristic (ROC) model was used across studies to determine sensitivity, specificity, and area under the full or partial ROC curve.
RESULTS: Nineteen articles consisting of a total of 5892 lesions were analyzed. Based on a 95% credible interval, DWI alone yielded a significantly better area under the ROC curve, sensitivity, and specificity (0.85, 0.69, 0.89, respectively) than T2-weighted imaging alone (0.75, 0.60, 0.76). Combined DWI and T2-weighted imaging (0.73, 0.70, 0.83) showed a similar area under the ROC curve but significantly better sensitivity and specificity than T2-weighted imaging alone. DWI and combined DWI and T2-weighted imaging yielded similar overall sensitivity, but DWI alone showed better overall specificity than combined DWI and T2-weighted imaging. At specificities of greater than 80%, combined DWI and T2-weighted imaging yielded a partial area under the ROC curve (0.138) similar to that of DWI alone (0.129) and was significantly better than the partial area under the ROC curve of T2-weighted imaging alone (0.070). DWI alone and combined DWI and T2-weighted imaging appear to be superior to dynamic contrast-enhanced imaging alone (area under the ROC curve, 0.79; sensitivity, 0.58; specificity, 0.82).
CONCLUSION: DWI appears to improve diagnostic performance and can be a useful adjunct to conventional anatomic imaging for identifying tumor foci in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22997374      PMCID: PMC3888871          DOI: 10.2214/AJR.11.7805

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  44 in total

1.  Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy.

Authors:  B Pickett; E Vigneault; J Kurhanewicz; L Verhey; M Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-01       Impact factor: 7.038

2.  Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.

Authors:  Jean Pouliot; Yongbok Kim; Etienne Lessard; I-Chow Hsu; Daniel B Vigneron; John Kurhanewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

3.  Use of MR exponential diffusion-weighted images to eradicate T2 "shine-through" effect.

Authors:  J M Provenzale; S T Engelter; J R Petrella; J S Smith; J R MacFall
Journal:  AJR Am J Roentgenol       Date:  1999-02       Impact factor: 3.959

4.  Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies.

Authors:  Daniel Portalez; Gautier Rollin; Pierre Leandri; Benjamin Elman; Patrick Mouly; Frédéric Jonca; Bernard Malavaud
Journal:  Eur Radiol       Date:  2010-08-03       Impact factor: 5.315

5.  Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.

Authors:  Joan C Vilanova; Carles Barceló-Vidal; Josep Comet; Maria Boada; Joaquim Barceló; Joana Ferrer; Joan Albanell
Journal:  AJR Am J Roentgenol       Date:  2011-06       Impact factor: 3.959

6.  Accuracy of MR imaging for staging prostate cancer: a meta-analysis to examine the effect of technologic change.

Authors:  S S Sonnad; C P Langlotz; J S Schwartz
Journal:  Acad Radiol       Date:  2001-02       Impact factor: 3.173

7.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.

Authors:  A E Wefer; H Hricak; D B Vigneron; F V Coakley; Y Lu; J Wefer; U Mueller-Lisse; P R Carroll; J Kurhanewicz
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

8.  Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging.

Authors:  Akihiro Tanimoto; Jun Nakashima; Hidaka Kohno; Hiroshi Shinmoto; Sachio Kuribayashi
Journal:  J Magn Reson Imaging       Date:  2007-01       Impact factor: 4.813

9.  High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice.

Authors:  Yiftach Roth; Thomas Tichler; Genady Kostenich; Jesus Ruiz-Cabello; Stephan E Maier; Jack S Cohen; Arie Orenstein; Yael Mardor
Journal:  Radiology       Date:  2004-06-23       Impact factor: 11.105

10.  Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis.

Authors:  Marc R Engelbrecht; Gerrit J Jager; Robert J Laheij; André L M Verbeek; H J van Lier; Jelle O Barentsz
Journal:  Eur Radiol       Date:  2002-04-19       Impact factor: 5.315

View more
  44 in total

1.  Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the evaluation of prostate cancer.

Authors:  Hebert Alberto Vargas; Edward Malnor Lawrence; Yousef Mazaheri; Evis Sala
Journal:  World J Radiol       Date:  2015-08-28

2.  Restriction spectrum imaging improves MRI-based prostate cancer detection.

Authors:  Kevin C McCammack; Natalie M Schenker-Ahmed; Nathan S White; Shaun R Best; Robert M Marks; Jared Heimbigner; Christopher J Kane; J Kellogg Parsons; Joshua M Kuperman; Hauke Bartsch; Rahul S Desikan; Rebecca A Rakow-Penner; Michael A Liss; Daniel J A Margolis; Steven S Raman; Ahmed Shabaik; Anders M Dale; David S Karow
Journal:  Abdom Radiol (NY)       Date:  2016-05

Review 3.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

4.  A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: a step towards practical implementation.

Authors:  Andriy Fedorov; Jacob Fluckiger; Gregory D Ayers; Xia Li; Sandeep N Gupta; Clare Tempany; Robert Mulkern; Thomas E Yankeelov; Fiona M Fennessy
Journal:  Magn Reson Imaging       Date:  2014-01-21       Impact factor: 2.546

5.  Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.

Authors:  Fiona M Fennessy; Rana R McKay; Clair J Beard; Mary-Ellen Taplin; Clare M Tempany
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

6.  Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer.

Authors:  Ely R Felker; Steven S Raman; Sepideh Shakeri; Sohrab A Mirak; Amirhossein M Bajgiran; Lorna Kwan; Pooria Khoshnoodi; Fuad F ElKhoury; Daniel J A Margolis; David Karow; David S K Lu; Nate White; Leonard S Marks
Journal:  AJR Am J Roentgenol       Date:  2019-04-30       Impact factor: 3.959

7.  Shear-wave elastography: role in clinically significant prostate cancer with false-negative magnetic resonance imaging.

Authors:  Li-Hua Xiang; Yan Fang; Jing Wan; Guang Xu; Ming-Hua Yao; Shi-Si Ding; Hui Liu; Rong Wu
Journal:  Eur Radiol       Date:  2019-05-29       Impact factor: 5.315

Review 8.  Implementation of Multi-parametric Prostate MRI in Clinical Practice.

Authors:  Andrea S Kierans; Samir S Taneja; Andrew B Rosenkrantz
Journal:  Curr Urol Rep       Date:  2015-08       Impact factor: 3.092

Review 9.  Current role of multiparametric magnetic resonance imaging for prostate cancer.

Authors:  Romaric Loffroy; Olivier Chevallier; Morgan Moulin; Sylvain Favelier; Pierre-Yves Genson; Pierre Pottecher; Gilles Crehange; Alexandre Cochet; Luc Cormier
Journal:  Quant Imaging Med Surg       Date:  2015-10

Review 10.  Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI.

Authors:  Ryan L Brunsing; Natalie M Schenker-Ahmed; Nathan S White; J Kellogg Parsons; Christopher Kane; Joshua Kuperman; Hauke Bartsch; Andrew Karim Kader; Rebecca Rakow-Penner; Tyler M Seibert; Daniel Margolis; Steven S Raman; Carrie R McDonald; Nikdokht Farid; Santosh Kesari; Donna Hansel; Ahmed Shabaik; Anders M Dale; David S Karow
Journal:  J Magn Reson Imaging       Date:  2016-08-16       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.